

CLAIM AMENDMENTS

1-13. (canceled)

14. (currently amended): A method to ~~evaluate the efficacy of a candidate~~ identify an antidote for a toxic compound which method comprises:

observing the intracellular localization pattern of at least one signal transduction protein in the presence and absence of the ~~toxin for which the antidote is being tested~~ toxic compound, said compound supplied at a concentration that is toxic so as to ascertain the localization pattern under toxic conditions (in the presence of ~~[[toxin]]~~ toxic compound) and under normal conditions (in the absence of ~~[[toxin]]~~ toxic compound);

observing the intracellular localization pattern of said at least one signal transduction protein in the presence of both the ~~[[toxin]]~~ toxic compound and ~~[[the]]~~ a candidate compound antidote;

comparing the localization pattern under toxic conditions in the presence of candidate ~~compound~~ antidote to the patterns under toxic and normal conditions;

whereby a ~~compound~~ antidote compound whose presence under toxic conditions restores the localization pattern to a pattern more closely resembling that under normal conditions is identified as an antidote to the ~~[[toxin]]~~ toxic compound;

wherein at least one of the following pertains:

said pattern is constructed by determining the presence, absence or level of said signal transduction protein(s) at at least three of nuclear, perinuclear, diffuse cytoplasmic, cytoplasmic fibril-associated and membrane-associated locations; or

said observing is by microscopy; or

said pattern is observed in fixed cells.

15. (currently amended): The method of claim 14 wherein the intracellular localization pattern is of at least two signal transduction proteins ~~is determined~~.

16. (currently amended): The method of claim 15 wherein the intracellular localization pattern is of a multiplicity of signal transduction proteins ~~is determined~~.

17. (currently amended): A method to identify a ~~treatment protocol for~~ compound ~~potentially useful to treat~~ a disease condition in which method comprises identifying inhibition of a cellular function the inhibition of which would ameliorate ameliorates said disease condition, which method comprises

observing the intracellular localization pattern of at least one signal transduction protein in the presence and the absence of a candidate compound;

~~comparing observing~~ the intracellular localization pattern ~~in the presence of the candidate compound with the intracellular localization pattern~~ of said signal transduction protein in the presence of a known an inhibitor compound, known to inhibit said cellular function;

comparing the observed intracellular localization patterns,

whereby similarity of said candidate compound is identified as potentially useful in treating the disease condition if the pattern observed with respect to in the presence of the candidate compound to that more closely resembles the pattern observed for said in the presence of a known inhibitor compound identifies said than does the pattern in the absence of the candidate compound; ~~as able to inhibit said cellular function, thus identifying said compound as a medicament to ameliorate the condition~~

wherein at least one of the following pertains:

said pattern is constructed by determining the presence, absence or level of said signal transduction protein(s) at at least three of nuclear, perinuclear, diffuse cytoplasmic, cytoplasmic fibril-associated and membrane-associated locations; or

said observing is by microscopy; or

said pattern is observed in fixed cells.

18. (canceled)

19. (currently amended): A method to ~~evaluate~~ identify a therapeutic protocol potentially effective for the treatment of a disease condition which method comprises

providing [[a]] an intracellular localization profile of a multiplicity of signal transduction proteins characteristic of said disease condition;

providing an intracellular localization profile of a multiplicity of signal transduction proteins characteristic of normal cells;

administering said protocol to cells or tissues exhibiting said profile characteristic of the disease condition; and

observing the effect of said therapeutic protocol on said profile, whereby a therapeutic protocol which results in conversion of said profile to a profile more closely ~~similar to~~ resembling that of normal cells identifies said protocol as ~~[[an]]~~ a potentially effective protocol;

wherein at least one of the following pertains:

said profile is constructed by determining the presence, absence or level of said signal transduction protein(s) at at least three of nuclear, perinuclear, diffuse cytoplasmic, cytoplasmic fibril-associated and membrane-associated locations; or

said observing is by microscopy; or

said profile is observed in fixed cells.

20. (canceled)

Please add the following claims:

21. (new): The method of claim 17, wherein the intracellular localization pattern is of at least two signal transduction proteins.

22. (new): The method of claim 21, wherein the intracellular localization pattern is of a multiplicity of signal transduction proteins.

23. (new): The method of claim 14, wherein said pattern is constructed by determining the presence, absence or level of said signal transduction protein(s) at at least three of nuclear, perinuclear, diffuse cytoplasmic, cytoplasmic fibril-associated and membrane-associated locations.

24. (new): The method of claim 17, wherein said pattern is constructed by determining the presence, absence or level of said signal transduction protein(s) at at least three of nuclear, perinuclear, diffuse cytoplasmic, cytoplasmic fibril-associated and membrane-associated locations.

25. (new): The method of claim 19, wherein said profile is constructed by determining the presence, absence or level of said signal transduction protein(s) at at least three of nuclear, perinuclear, diffuse cytoplasmic, cytoplasmic fibril-associated and membrane-associated locations.
26. (new): The method of claim 14, wherein said observing is by microscopy.
27. (new): The method of claim 17, wherein said observing is by microscopy.
28. (new): The method of claim 19, wherein said observing is by microscopy.
29. (new): The method of claim 14, wherein the localization pattern is observed in fixed cells.
30. (new): The method of claim 17, wherein the localization pattern is observed in fixed cells.
31. (new): The method of claim 19, wherein the localization profile is observed in fixed cells.